Zheng Quan Ri Bao Wang·2026-02-13 13:31Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yingjixin Technology Co., Ltd. for misleading statements related to information disclosure, particularly concerning their involvement in the brain-computer interface (BCI) chip sector [1][3]. Group 1: Investigation and Regulatory Actions - The CSRC has opened a case against Yingjixin for misleading disclosures made on January 6, where the company claimed to have launched a chip for BCI applications, which was later clarified to be in the market cultivation phase and not significantly impacting company performance [1][2]. - Other companies, including Ningbo Rongbai New Energy Technology Co., Ltd. and Shenzhen Yahui Long Biotechnology Co., Ltd., have also been investigated for similar misleading disclosures, with Rongbai facing a proposed fine of 9.5 million yuan [1][4]. Group 2: Misleading Information and Market Reactions - Yingjixin's January 6 response on the Shanghai Stock Exchange's E-interaction platform was deemed misleading as it did not accurately reflect the product's launch entity, sales scale, and the significant technical differences from international products [2][3]. - Following the misleading information, Yingjixin's stock price rose by 4.51% on the day of the announcement, despite the subsequent clarification that the product was not yet commercially viable [2][3]. Group 3: Broader Industry Implications - The regulatory actions against multiple companies signal a clear stance from authorities against "hype-driven" disclosures that mislead investors, emphasizing the need for accurate and complete information [4][7]. - Companies are reminded that voluntary disclosures are not exempt from regulations, and misleading statements can lead to significant penalties and regulatory scrutiny [7].